- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 31.03. | ACC 25: Oral semaglutide reduces cardiovascular events in T2D patients | ||
| 28.03. | Novo Nordisk strikes $1bn deal for Lexicon's oral obesity drug | ||
| 28.03. | Macau approves IASO Bio's multiple myeloma therapy | ||
| 28.03. | MSD's subcutaneous Keytruda non-inferior to IV version of blockbuster drug | ||
| 28.03. | Weill Cancer Hub East launches to transform treatment | ||
| 28.03. | Genmab's Tivdak approved in Japan for advanced cervical cancer | ||
| 27.03. | Soleno wins FDA approval for Prader-Willi hyperphagia treatment | ||
| 27.03. | HHS announces major workforce cuts and reorganisation | ||
| 27.03. | How bioconjugation is unlocking the next generation of drug development | ||
| 27.03. | Ionis and Sobi agree on olezarsen commercialisation | ||
| 27.03. | Blockbuster potential drugs ruled the 2024 pipeline with 53% rise over 2023 | ||
| 27.03. | AGA overhauls UC treatment pathway: early, high-efficacy therapies now preferred | ||
| 27.03. | Tribune gains funds to advance scar tissue therapies | ||
| 27.03. | EC approves MSD's pneumococcal 21-valent conjugate Capvaxive | ||
| 26.03. | Unmatched quality in pharmaceutical logistics: Why it matters | ||
| 26.03. | FDA approves GSK's Blujepa for uncomplicated UTIs | ||
| 26.03. | Big pharma faces headwinds in China as vaccine sales decline | ||
| 26.03. | MHRA launches new monthly safety bulletins | ||
| 26.03. | Cassava ends simufilam Alzheimer's programme after second Phase III failure | ||
| 26.03. | FDA fast tracks Sanofi's mRNA vaccine for chlamydia | ||
| 26.03. | Character Biosciences gains $93m for precision eye disease therapies | ||
| 26.03. | MSD makes licence agreement with Hengrui Pharma for Lp(a) inhibitor | ||
| 25.03. | GSK and UK researchers plan to study Shingrix and dementia risk reduction link | ||
| 25.03. | Novo Nordisk earmarks $2bn for Chinese "triple G" weight loss shot | ||
| 25.03. | Alumis and Kaken sign agreement in Japan to develop ESK-001 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
